The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
AAV vectors are widely used in gene therapy for their strong therapeutic potential
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
